AbbVie Inc.

🇺🇸New York Stock Exchange
Back to all articles
AbbVie Inc. stock analysis ABBV overview
Somewhat Bullish +50

Battle of Big Pharma: Is AbbVie Stock Pulling Ahead of Pfizer?

🏥 AbbVie and Pfizer are two leading U.S. drugmakers with diverse portfolios across oncology, immunology, neuroscience, and vaccines.

💊 AbbVie offset Humira's loss of exclusivity with newer immunology therapies Skyrizi and Rinvoq, which now generate about half of its revenue.

🔬 Both companies have robust R&D pipelines intended to drive innovation and long-term growth in their respective sectors.

🧬 Pfizer strengthened its oncology position with the 2023 Seagen acquisition, contributing to an 8% revenue increase in 2025.

💉 Pfizer's non-COVID revenues are improving driven by products like Vyndaqel, Padcev, and Eliquis, with recently acquired products rising 14% in 2025.

🤝 Pfizer invested approximately $9 billion in M&A deals in 2025 to rebuild its pipeline, including acquisitions of Metsera and licensing from 3SBio.

🧪 Pfizer plans 20 pivotal studies in 2026, including ten for obesity candidates from the Metsera acquisition.

⚠️ Pfizer's 2026 outlook shows mostly flat to slightly negative growth due to declining COVID sales, Medicare Part D impacts, and upcoming patent expirations.

📉 The Zacks Consensus Estimate for Pfizer's 2026 implies a year-over-year decrease of 2.5% in sales and 7.5% in earnings.

💰 Pfizer offers an impressive dividend yield of around 6.3% alongside significant cost reduction efforts to improve R&D productivity.

📈 AbbVie's Skyrizi and Rinvoq combined sales reached $26 billion in 2025, growing over 40%, with expectations for more than $31 billion in 2026.

🧠 AbbVie's neuroscience portfolio saw a 20% sales increase to $10.8 billion in 2025, driven by Botox Therapeutic and migraine drugs Ubrelvy and Qulipta.

🔬 AbbVie invested over $5 billion in 2025 for M&A deals to bolster its pipeline in immunology, oncology, and neuroscience.

⚠️ AbbVie faces near-term headwinds including Humira biosimilar erosion, slowing oncology sales, and a 5.9% decline in aesthetics portfolio sales.

📊 The Zacks Consensus Estimate for AbbVie's 2026 implies a 9.6% sales increase and 45.3% earnings growth compared to the previous year.

📉 Pfizer stock has risen 24.2% over the past year, while AbbVie jumped 21.3%, outperforming or matching industry returns of 25.8%.

📉 AbbVie trades at a lower forward P/E ratio of 14.14 compared to Pfizer's 9.29 and the industry average of 17.42.

Bullish Signals
  • AbbVie successfully offset the impact of Humira's loss of exclusivity with its newer immunology therapies Skyrizi and Rinvoq, which generated combined sales of $26.0 billion in 2025 representing year-over-year growth of more than 40%.
  • In 2026, AbbVie expects combined Skyrizi and Rinvoq sales to exceed $31 billion, signaling strong top-line growth prospects for its core immunology business.
  • AbbVie's neuroscience portfolio contributed significantly to top-line growth with sales increasing almost 20% to $10.8 billion in 2025 driven by Botox Therapeutic, Vraylar, and newer migraine drugs Ubrelvy and Qulipta.
  • Pfizer achieved an impressive dividend yield of around 6.3%, providing attractive income potential for investors while maintaining strong positions in oncology with its acquired products driving 8% revenue growth in 2025.
  • Pfizer invested around $9 billion in M&A deals in 2025 including the acquisition of Metsera and licensing from 3SBio, which adds ultra-long-acting obesity candidates and pipeline depth for future innovation.
  • AbbVie invested more than $5 billion in 2025 to acquire innovative pipeline candidates, demonstrating a strong commitment to bolstering its early-stage pipeline for long-term growth.
  • The Zacks Consensus Estimate for AbbVie's 2026 earnings shows a year-over-year increase of 45.3%, reflecting robust market expectations despite some near-term headwinds.
  • Pfizer expects its recently launched and acquired products to record continued double-digit growth in 2026, including specific plans to start 20 pivotal studies that include 10 for obesity candidates from the Metsera acquisition.
Risk Factors
  • Pfizer's 2026 revenue and earnings guidance failed to impress investors, representing mostly flat to slightly negative growth.
  • Pfizer faces declining sales of its COVID products, unfavorable impact from Medicare Part D redesign, and upcoming patent expirations for key products like Eliquis, Vyndaqel, Ibrance, Xeljanz and Xtandi in the 2026-2030 period.
  • AbbVie faces near-term headwinds including Humira's biosimilar erosion, a slight slowdown in oncology sales, and declining sales of its Aesthetics unit due to macro challenges with a 5.9% decline in global sales in 2025.
  • The Zacks Consensus Estimate for AbbVie's 2027 earnings has decreased from $16.15 to $16.14 per share over the past 60 days, indicating weakening market expectations.
  • AbbVie's shares currently trade higher than its five-year mean of 13.81, suggesting potential valuation concerns despite trading at 14.14 forward earnings.
Full Analysis
Pfizer and AbbVie stand as two of the leading U.S. drugmakers with diverse therapeutic portfolios, yet their current trajectories offer distinct investment narratives. Pfizer derives roughly 27% of its revenues from oncology, a segment strengthened by the 2023 acquisition of Seagen, which drove an 8% increase in oncology revenues during 2025 through drugs like Xtandi and Padcev. The company has successfully reduced its reliance on COVID business, with non-COVID operational revenues up 14% year over year in 2025 driven by products such as Vyndaqel and Eliquis. Pfizer also plans to initiate 20 pivotal studies in 2026, including 10 for obesity candidates acquired from Metsera and four for the dual PD-1/VEGF inhibitor PF-08634404 from 3SBio, expecting continued double-digit growth from recent acquisitions. Additionally, Pfizer maintains a dividend yield of approximately 6.3% and has invested around $9 billion in M&A deals in 2025, though it faces headwinds including upcoming patent expirations for key products like Eliquis and Xtandi between 2026 and 2030. In contrast, AbbVie has effectively offset the expiration of its blockbuster Humira, which once contributed over 50% of total revenues, through the success of its immunology therapies Skyrizi and Rinvoq. These newer drugs generated combined sales of $26.0 billion in 2025 with year-over-year growth exceeding 40%, projecting sales above $31 billion for 2026. Immunology now accounts for about half of AbbVie's total revenues, while its neuroscience portfolio grew nearly 20% to $10.8 billion in 2025 driven by Botox Therapeutic and migraine drugs Ubrelvy and Qulipta. The company also invested more than $5 billion in M&A deals in 2025, focusing on early-stage pipelines in immunology, oncology, and neuroscience, although it faces challenges such as Humira's biosimilar erosion and a 5.9% decline in aesthetics portfolio sales during the same period. Analyst estimates paint a divergent picture for the two companies regarding 2026 financial performance. The Zacks Consensus Estimate projects Pfizer's 2026 sales to decline by approximately 2.5% and earnings per share (EPS) to fall by 7.5%, with EPS rising slightly from $2.97 to $2.98 in 2026 before stabilizing at $2.82 for 2027. Conversely, AbbVie is expected to see sales growth of 9.6% and a substantial 45.3% increase in EPS for 2026, with estimates rising from $14.46 to $14.53 per share. Stock performance over the past year reflects this dynamic, with Pfizer shares up 24.2% compared to AbbVie's 21.3%, while the broader industry returned 25.8%. Valuation metrics also differ, with Pfizer trading at a forward price/earnings ratio of 9.29 compared to AbbVie's 14.14, though AbbVie currently trades above its five-year mean P/E of 13.81.